223 related articles for article (PubMed ID: 15810646)
1. Efficacy of mesalazine in the treatment of symptomatic diverticular disease.
Di Mario F; Aragona G; Leandro G; Comparato G; Fanigliulo L; Cavallaro LG; Cavestro GM; Iori V; Maino M; Moussa AM; Gnocchi A; Mazzocchi G; Franzé A
Dig Dis Sci; 2005 Mar; 50(3):581-6. PubMed ID: 15810646
[TBL] [Abstract][Full Text] [Related]
2. Prevention of complications and symptomatic recurrences in diverticular disease with mesalazine: a 12-month follow-up.
Comparato G; Fanigliulo L; Cavallaro LG; Aragona G; Cavestro GM; Iori V; Maino M; Mazzocchi G; Muzzetto P; Colla G; Sianesi M; Franzé A; Mario FD
Dig Dis Sci; 2007 Nov; 52(11):2934-41. PubMed ID: 17410435
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease.
Brandimarte G; Tursi A
Med Sci Monit; 2004 May; 10(5):PI70-3. PubMed ID: 15114281
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
Tursi A; Brandimarte G; Daffinà R
Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
[TBL] [Abstract][Full Text] [Related]
5. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis.
Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M
Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1397-1404. PubMed ID: 28387885
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon.
Latella G; Pimpo MT; Sottili S; Zippi M; Viscido A; Chiaramonte M; Frieri G
Int J Colorectal Dis; 2003 Jan; 18(1):55-62. PubMed ID: 12458383
[TBL] [Abstract][Full Text] [Related]
7. Intermittent versus every-day mesalazine therapy in preventing complications of diverticular disease: a long-term follow-up study.
Tursi A; Di Mario F; Brandimarte G; Elisei W; Picchio M; Loperfido S; Dal Bo' N; Ferrara F; Marcello R; Heras Salvat H; Scarpignato C
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(23):3244-8. PubMed ID: 24338468
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of rifaximin on symptoms of uncomplicated diverticular disease of the colon. A pilot multicentre open trial. Diverticular Disease Study Group.
Papi C; Ciaco A; Koch M; Capurso L
Ital J Gastroenterol; 1992 Oct; 24(8):452-6. PubMed ID: 1330083
[TBL] [Abstract][Full Text] [Related]
9. Transient lactose malabsorption in patients affected by symptomatic uncomplicated diverticular disease of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W
Dig Dis Sci; 2006 Mar; 51(3):461-5. PubMed ID: 16614952
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial.
Papi C; Ciaco A; Koch M; Capurso L
Aliment Pharmacol Ther; 1995 Feb; 9(1):33-9. PubMed ID: 7766741
[TBL] [Abstract][Full Text] [Related]
11. Mesalazine to treat symptomatic uncomplicated diverticular disease and to prevent acute diverticulitis occurrence. A systematic review with meta-analysis of randomized, placebo-controlled trials.
Picchio M; Elisei W; Tursi A
J Gastrointestin Liver Dis; 2018 Sep; 27(3):291-297. PubMed ID: 30240473
[TBL] [Abstract][Full Text] [Related]
12. Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease.
Tursi A; Brandimarte G; Elisei W; Giorgetti GM; Inchingolo CD; Aiello F
Dig Liver Dis; 2008 Sep; 40(9):737-42. PubMed ID: 18387861
[TBL] [Abstract][Full Text] [Related]
13. Mesalazine for People with Diverticular Disease: A Systematic Review of Randomized Controlled Trials.
Iannone A; Ruospo M; Wong G; Barone M; Principi M; Di Leo A; Strippoli GFM
Can J Gastroenterol Hepatol; 2018; 2018():5437135. PubMed ID: 30320044
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.
Tursi A; Brandimarte G; Elisei W; Picchio M; Forti G; Pianese G; Rodino S; D'Amico T; Sacca N; Portincasa P; Capezzuto E; Lattanzio R; Spadaccini A; Fiorella S; Polimeni F; Polimeni N; Stoppino V; Stoppino G; Giorgetti GM; Aiello F; Danese S
Aliment Pharmacol Ther; 2013 Oct; 38(7):741-51. PubMed ID: 23957734
[TBL] [Abstract][Full Text] [Related]
15. Mesalazine for diverticular disease of the colon--a new role for an old drug.
Tursi A
Expert Opin Pharmacother; 2005 Jan; 6(1):69-74. PubMed ID: 15709884
[TBL] [Abstract][Full Text] [Related]
16. [Role of rifaximin in the treatment of colonic diverticular disease].
Moretti A; Spagnolo A; Mangone M; Chiesara F; Aratari A; Papi C; Koch M
Clin Ter; 2012; 163(1):33-8. PubMed ID: 22362232
[TBL] [Abstract][Full Text] [Related]
17. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease.
Stallinger S; Eller N; Högenauer C
Wien Klin Wochenschr; 2014 Jan; 126(1-2):9-14. PubMed ID: 24240607
[TBL] [Abstract][Full Text] [Related]
18. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.
Festi D; Colecchia A
Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809
[No Abstract] [Full Text] [Related]
19. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease.
Gatta L; Di Mario F; Curlo M; Vaira D; Pilotto A; Lucarini P; Lera M; Enkleda K; Franzé A; Scarpignato C
Intern Emerg Med; 2012 Apr; 7(2):133-7. PubMed ID: 21279478
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin in the management of colonic diverticular disease.
Latella G; Scarpignato C
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):585-98. PubMed ID: 19929580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
